The projects will range from discovery to developmental stage programs and reach across multiple research sites of Pfizer’s Global R&D organization. Financial terms of the transaction include an upfront technology access fee along with research support payments by Pfizer.
Under the terms of the collaborative agreement, ActivX will apply its novel chemical technologies and high-throughput protein analysis to a number of Pfizer programs spanning drug discovery, proteomic profiling, compound selectivity and biological activity, and mechanisms of toxicity.
“Over the past year, ActivX has provided important initial data on the utility of its technology to impact Pfizer programs,” commented Dr John LaMattina, president of Global R&D at Pfizer. “This expanded, multi-site collaboration will permit Pfizer to fully explore the technology’s scope and value in a variety of R&D settings.”